FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Lotze

Research Profile

Living Beings

Anatomy

Chemicals & Drugs

Disorders

Procedures

Physiology

Transfection

Co-author Network

Publications

TOP 3
Qiuhong Zhang; Herbert J Zeh; Rui Kang; Michael T Lotze; Daolin Tang
DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death.
Rui Kang; Michael T Lotze; Daolin Tang; Herbert J Zeh Iii
Autophagy is required for IL-2-mediated fibroblast growth.
Philip J Vernon; Pawel Kalinski; Rui Kang; Michael T Lotze; Tara J Loux; Ravi Muthuswamy; Nicole E Schapiro; Daolin Tang; Herbert J Zeh
The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Lotze (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Qiuhong Zhang; Herbert J Zeh; Rui Kang; Michael T Lotze; Daolin Tang
DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death.
Autophagy 2013;9(4):451-8.
2013: Rui Kang; Michael T Lotze; Daolin Tang; Herbert J Zeh Iii
Autophagy is required for IL-2-mediated fibroblast growth.
Experimental cell research 2013;319(4):556-65.
2013: Philip J Vernon; Pawel Kalinski; Rui Kang; Michael T Lotze; Tara J Loux; Ravi Muthuswamy; Nicole E Schapiro; Daolin Tang; Herbert J Zeh
The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.
Journal of immunology (Baltimore, Md. : 1950) 2013;190(3):1372-9.
2013: Guanqiao Li; Xiaoyan Liang; Michael T Lotze
HMGB1: The Central Cytokine for All Lymphoid Cells.
Frontiers in immunology 2013;4():68.
2013: Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
American journal of cancer research 2013;3(1):1-20.
2012: Siuwah Tang; Michael T Lotze
The power of negative thinking: which cells limit tumor immunity?
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(19):5157-9.
2012: Daolin Tang; Michael T Lotze
Tumor immunity times out: TIM-3 and HMGB1.
Nature immunology 2012;13(9):808-10.
2012: Daolin Tang; Herbert J Zeh; Carolyn B Coyne; Rui Kang; Michael T Lotze
PAMPs and DAMPs: signal 0s that spur autophagy and immunity.
Immunological reviews 2012;249(1):158-75.
2012: Michael T Lotze; William J Buchser; Xiaoyan Liang
Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity.
Autophagy 2012;8(8):1264-6.
2012: William J Buchser; Thomas C Laskow; Hui-Min Lin; Philip J Pavlik; Michael T Lotze
Cell-mediated autophagy promotes cancer cell survival.
Cancer research 2012;72(12):2970-9.
2012: Rui Kang; Michael T Lotze; Daolin Tang; Herbert J Zeh
AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway.
Autophagy 2012;8(6):989-91.
2012: Xiaoyan Liang; Per Basse; William J Buchser; Michael de Vera; Patricia A Loughran; Bennett Van Houten; Tao Wang; Herbert J Zeh; Donna B Stolz; Antonio Romo de Vivar Chavez; Michael T Lotze
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression.
Cancer research 2012;72(11):2791-801.
2012: Wei Yan; Jon S Cardinal; Ying Chang; David A Geller; Hai Huang; Xiaoyan Liang; Michael T Lotze; Satdarshan Pal S. Monga; Stephen H Thorne; Allan Tsung
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases.
Hepatology (Baltimore, Md.) 2012;55(6):1863-75.
2012: Kristen M Livesey; Michael T Lotze; Rui Kang; Herbert J Zeh; Daolin Tang
Direct molecular interactions between HMGB1 and TP53 in colorectal cancer.
Autophagy 2012;8(5):846-8.
2012: Rui Kang; Alyssa Krasinskas; Kristen M Livesey; Michael T Lotze; Tara Loux; Nicole E Schapiro; Daolin Tang; Philip Vernon; Herbert J Zeh
The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(18):7031-6.
2012: Daolin Tang; Timothy R Billiar; Michael T Lotze
A Janus tale of two active high mobility group box 1 (HMGB1) redox states.
Molecular medicine (Cambridge, Mass.) 2012;18():1360-2.
2012: Sebnem Unlu; E na Wang; Herbert J Zeh; Ena Wang; Marco E Bianchi; Ivan Martinez; Daolin Tang; Siuwah Tang; Michael T Lotze
Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells.
PloS one 2012;7(6):e38899.
2011: Daolin Tang; Herbert J Zeh; Rui Kang; Kristen M Livesey; Michael T Lotze
High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress.
Antioxidants & redox signaling 2011;15(8):2185-95.
2011: Rui Kang; Kristen M Livesey; Michael T Lotze; Nicole E Schapiro; Daolin Tang; Herbert J Zeh
The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury.
Antioxidants & redox signaling 2011;15(8):2175-84.
2011: Rui Kang; Kristen M Livesey; Michael T Lotze; Herbert J Zeh; Daolin Tang
HMGB1 as an autophagy sensor in oxidative stress.
Autophagy 2011;7(8):904-6.
2011: Daolin Tang; Rui Kang; Kristen M Livesey; Guido Kroemer; Timothy R Billiar; Bennett Van Houten; Herbert J Zeh; Michael T Lotze
High-mobility group box 1 is essential for mitochondrial quality control.
Cell metabolism 2011;13(6):701-11.
2011: D Tang; Michael T Lotze; R Kang; Herbert J Zeh
Apoptosis promotes early tumorigenesis.
Oncogene 2011;30(16):1851-4.
2011: Rui Kang; Michael T Lotze; Daolin Tang; Herbert J Zeh
RAGE regulates autophagy and apoptosis following oxidative injury.
Autophagy 2011;7(4):442-4.
2011: R Kang; Herbert J Zeh; Michael T Lotze; D Tang
The Beclin 1 network regulates autophagy and apoptosis.
Cell death and differentiation 2011;18(4):571-80.
2011: Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
High-mobility group box 1, oxidative stress, and disease.
Antioxidants & redox signaling 2011;14(7):1315-35.
2010: D Tang; R Kang; C-W Cheh; K M Livesey; Xiaoyan Liang; N E Schapiro; R Benschop; L J Sparvero; Andrew A Amoscato; Kevin Tracey; Herbert J Zeh; Michael T Lotze
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells.
Oncogene 2010;29(38):5299-310.
2010: Daolin Tang; Rui Kang; Kristen M Livesey; Chun-Wei Cheh; Adam Farkas; Patricia A Loughran; George Hoppe; Marco E Bianchi; Kevin Tracey; Herbert J Zeh; Michael T Lotze
Endogenous HMGB1 regulates autophagy.
The Journal of cell biology 2010;190(5):881-92.
2010: Hideho Okada; Gary Kohanbash; Michael T Lotze
MicroRNAs in immune regulation--opportunities for cancer immunotherapy.
The international journal of biochemistry & cell biology 2010;42(8):1256-61.
2010: Erica John; Thomas C Laskow; William J Buchser; Bruce R Pitt; Per H Basse; Lisa H Butterfield; Pawel Kalinski; Michael T Lotze
Zinc in innate and adaptive tumor immunity.
Journal of translational medicine 2010;8():118.
2010: Kotaro Sasaki; Gary Kohanbash; Aki Hoji; Ryo Ueda; Heather A McDonald; Todd A Reinhart; Jeremy Martinson; Michael T Lotze; Francesco M Marincola; Ena Wang; Mitsugu Fujita; Hideho Okada
miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy.
Journal of translational medicine 2010;8():17.
2010: Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
High-mobility group box 1 and cancer.
Biochimica et biophysica acta 2010;1799(1-2):131-40.
2009: Antonio Romo de Vivar Chavez; William Buchser; Per H Basse; Xiaoyan Liang; Leonard J Appleman; Jodi K Maranchie; Herbert J Zeh; Michael E de Vera; Michael T Lotze
Pharmacologic administration of interleukin-2.
Annals of the New York Academy of Sciences 2009;1182():14-27.
2009: Kristen M Livesey; Daolin Tang; Herbert J Zeh; Michael T Lotze
Autophagy inhibition in combination cancer treatment.
Current opinion in investigational drugs (London, England : 2000) 2009;10(12):1269-79.
2009: Xiaoyan Liang; Antonio Romo de Vivar Chavez; Nicole E Schapiro; Patricia Loughran; Stephen H Thorne; Andrew A Amoscato; Herbert J Zeh; Donna Beer-Stolz; Michael T Lotze; Michael de Vera
Ethyl pyruvate administration inhibits hepatic tumor growth.
Journal of leukocyte biology 2009;86(3):599-607.
2009: Pinhua Pan; Jon Cardinal; Rajeev Dhupar; Matthew R Rosengart; Michael T Lotze; David A Geller; Timothy R Billiar; Allan Tsung
Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality.
Journal of leukocyte biology 2009;86(3):625-32.
2009: Shaival H Davé; Jeremy S Tilstra; Katsuyoshi Matsuoka; Fengling Li; Richard A DeMarco; Donna Beer-Stolz; Antonia R Sepulveda; Mitchell P Fink; Michael T Lotze; Scott Plevy
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis.
Journal of leukocyte biology 2009;86(3):633-43.
2009: Ryo Ueda; Gary Kohanbash; Kotaro Sasaki; Mitsugu Fujita; Xinmei Zhu; Edward R Kastenhuber; Heather A McDonald; Douglas M Potter; Ronald L Hamilton; Michael T Lotze; Saleem A Khan; Robert W Sobol; Hideho Okada
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(26):10746-51.
2009: Mahmut Tör; Michael T Lotze; Nicholas Holton
Receptor-mediated signalling in plants: molecular patterns and programmes.
Journal of experimental botany 2009;60(13):3645-54.
2009: Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.
Journal of translational medicine 2009;7():17.
2009: Antonio Romo de Vivar Chavez; Michael de Vera; Xiaoyan Liang; Michael T Lotze
The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.
Medical oncology (Northwood, London, England) 2009;26 Suppl 1():3-12.
2008: Kristen M Livesey; Daolin Tang; Herbert J Zeh; Michael T Lotze
Not just nuclear proteins: 'novel' autophagy cancer treatment targets - p53 and HMGB1.
Current opinion in investigational drugs (London, England : 2000) 2008;9(12):1259-63.
2008: Stergios J Moschos; Maja Mandic; John M Kirkwood; Walter J Storkus; Michael T Lotze
Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
Clinical immunology (Orlando, Fla.) 2008;127(2):123-9.
2008: Michael T Lotze; Gerald Nepom
A nexus of science and clinical immunology: the Federation of Clinical Immunology Societies and the FOCIS Centers of Excellence.
Clinical immunology (Orlando, Fla.) 2008;127(2):119-20.
2008: Jukka Vakkila; Richard A DeMarco; Michael T Lotze
Coordinate NF-kappaB and STAT1 activation promotes development of myeloid type 1 dendritic cells.
Scandinavian journal of immunology 2008;67(3):260-9.
2008: Therese Ostberg; Heidi Wähämaa; Karin Palmblad; Norimasa Ito; Pernilla Stridh; Maria Shoshan; Michael T Lotze; Helena Erlandsson Harris; Ulf Andersson
Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis.
Arthritis research & therapy 2008;10(1):R1.
2007: Adam M Farkas; Tina M Kilgore; Michael T Lotze
Detecting DNA: getting and begetting cancer.
Current opinion in investigational drugs (London, England : 2000) 2007;8(12):981-6.
2007: Michael T Lotze; Herbert J Zeh; Anna Rubartelli; Louis J Sparvero; Andrew A Amoscato; Newell R Washburn; Michael Devera; Xiaoyan Liang; Mahmut Tör; Timothy R Billiar
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity.
Immunological reviews 2007;220():60-81.
2007: Xiang Da Eric Dong; Norimasa Ito; Michael T Lotze; Richard A DeMarco; Petar Popovic; Stuart H Shand; simon simon watkins; Steven E Winikoff; Charles K Brown; David L Bartlett; Herbert J Zeh
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(6):596-606.
2007: Jessica E Ellerman; Charles K Brown; Michael de Vera; Herbert J Zeh; Timothy R Billiar; Anna Rubartelli; Michael T Lotze
Masquerader: high mobility group box-1 and cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2836-48.
2007: Michael T Lotze; Jonathan Gray
A life in passing: Jonathan Gray.
Journal of translational medicine 2007;5():54.
2007: Ramin Lotfi; James J Lee; Michael T Lotze
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(1):16-28.
2007: Allan Tsung; Ning Zheng; Geetha Jeyabalan; Kunihiko Izuishi; John R Klune; David A Geller; Michael T Lotze; Lina Lu; Timothy R Billiar
Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury.
Journal of leukocyte biology 2007;81(1):119-28.
2007: Norimasa Ito; Richard A DeMarco; Robbie B Mailliard; Jie Han; Hannah Rabinowich; Pawel Kalinski; Donna B Stolz; Herbert J Zeh; Michael T Lotze
Cytolytic cells induce HMGB1 release from melanoma cell lines.
Journal of leukocyte biology 2007;81(1):75-83.
2006: Petar Popovic; Richard A DeMarco; Michael T Lotze; Steven E Winikoff; David L Bartlett; Arthur M Krieg; Z Sheng Guo; Charles K Brown; Kevin Tracey; Herbert J Zeh
High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(12):8701-7.
2006: Yalan Wang; Ning Zheng; Zhengbin Lu; Wenhan Wu; Lianfu Wang; Atsunori Nakao; Michael T Lotze; Carrie E Langer; John J Fung; Shiguang Qian; Lina Lu
In vivo expansion of two distinct dendritic cells in mouse livers and its impact on liver immune regulation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2006;12(12):1850-61.
2006: David T Montag; Michael T Lotze
Rapid flow cytometric measurement of cytokine-induced phosphorylation pathways [CIPP] in human peripheral blood leukocytes.
Clinical immunology (Orlando, Fla.) 2006;121(2):215-26.
2006: David T Montag; Michael T Lotze
Successful simultaneous measurement of cell membrane and cytokine induced phosphorylation pathways [CIPP] in human peripheral blood mononuclear cells.
Journal of immunological methods 2006;313(1-2):48-60.
2006: Kunihiko Izuishi; Allan Tsung; Geetha Jeyabalan; Nathan D Critchlow; Jianhua Li; Kevin Tracey; Richard A DeMarco; Michael T Lotze; Mitchell Fink; David A Geller; Timothy R Billiar
Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(12):7154-8.
2006: Jukka Vakkila; Ronald Jaffe; Marilyn Michelow; Michael T Lotze
Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2049-54.
2006: Leonardo D'Aiuto; Richard De Marco; Nwanegbo Edward; Annalisa Rizzo; J Richard Chaillet; Angela Montecalvo; Michael T Lotze; Andrea Gambotto
Evidence of the capability of the CMV enhancer to activate in trans gene expression in mammalian cells.
DNA and cell biology 2006;25(3):171-80.
2006: Ran Tao; Lianfu Wang; Cheng-Hsu Chen; Shi-Ho Wang; Richard A DeMarco; Michael T Lotze; Ngoc L Thai; John J Fung; Lina Lu; Shiguang Qian
Mechanistic insights into achievement of cardiac allograft long-term survival by treatment with immature dendritic cells and sub-dose sirolimus.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2006;25(3):310-9.
2006: Masatoshi Eto; Jaafar Bennouna; Oriana C Hunter; Michael T Lotze; Andrew A Amoscato
Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells.
International journal of urology : official journal of the Japanese Urological Association 2006;13(2):148-56.
2005: Allan Tsung; Rosemary A Hoffman; Kunihiko Izuishi; Nathan D Critchlow; Atsunori Nakao; Meagan H Chan; Michael T Lotze; David A Geller; Timothy R Billiar
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(11):7661-8.
2005: Z Sheng Guo; Arpana M Naik; Mark E O'Malley; Petar Popovic; Richard A DeMarco; Yun Hu; Xiaoyu Yin; Shuting Yang; Herbert J Zeh; Bernard Moss; Michael T Lotze; David L Bartlett
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.
Cancer research 2005;65(21):9991-8.
2005: Muneo Numasaki; Mika Watanabe; Takashi Suzuki; Hidenori Takahashi; Akira Nakamura; Florencia McAllister; Takanori Hishinuma; Junichi Goto; Michael T Lotze; Jay K Kolls; Hidetada Sasaki
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(9):6177-89.
2005: Pawel Kalinski; Robbie B Mailliard; Adam Giermasz; Herbert J Zeh; Per H Basse; David L Bartlett; John M Kirkwood; Michael T Lotze; Ronald Herberman
Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Expert opinion on biological therapy 2005;5(10):1303-15.
2005: Hidenori Takahashi; Muneo Numasaki; Michael T Lotze; Hidetada Sasaki
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells.
Immunology letters 2005;98(2):189-93.
2005: Allan Tsung; Rohit Sahai; Hiroyuki Tanaka; Atsunori Nakao; Mitchell Fink; Michael T Lotze; Huan Yang; Jianhua Li; Kevin Tracey; David A Geller; Timothy R Billiar
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.
The Journal of experimental medicine 2005;201(7):1135-43.
2005: Michael T Lotze; Kevin Tracey
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.
Nature reviews. Immunology 2005;5(4):331-42.
2005: Michael T Lotze; Ena Wang; Francesco M Marincola; Nabil Hanna; Peter J Bugelski; Christine A Burns; George Coukos; Nitin Damle; Tony E Godfrey; W Martin Howell; Monica C Panelli; Michael A Perricone; Emanuel F Petricoin; Guido Sauter; Carmen Scheibenbogen; Steve Shivers; D Lansing Taylor; John N Weinstein; Theresa L Whiteside
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(2):79-119.
2005: Richard A DeMarco; Mitchell Fink; Michael T Lotze
Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1.
Molecular immunology 2005;42(4):433-44.
2005: Jukka Vakkila; Richard A DeMarco; Michael T Lotze
Imaging analysis of STAT1 and NF-kappaB translocation in dendritic cells at the single cell level.
Drug discovery today 2005;Suppl():19-30.
2005: Herbert J Zeh; Steven E Winikoff; Douglas Landsittel; Elieser Gorelik; Adele M Marrangoni; Lyudmila Velikokhatnaya; Matthew T Winans; K Lee; A Moser; D Bartlett; Michael T Lotze; Jill M Siegfried; david whitcomb; G Papacristou; Adam Slivka; William L Bigbee; Anna Lokshin
Multianalyte profiling of serum cytokines for detection of pancreatic cancer.
Cancer biomarkers : section A of Disease markers 2005;1(6):259-69.
2005: Milos Hauskrecht; Richard Pelikan; David E Malehorn; William L Bigbee; Michael T Lotze; Herbert J Zeh; david whitcomb; James Lyons-Weiler
Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles.
Applied bioinformatics 2005;4(4):227-46.
2005: Jukka Vakkila; Michael T Lotze; Connie Riga; Ronald Jaffe
A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2005;8(1):43-51.
2005: Herbert J Zeh; Michael T Lotze
Addicted to death: invasive cancer and the immune response to unscheduled cell death.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(1):1-9.
2004: Michael T Lotze; Richard A DeMarco
Dying dangerously: Necrotic cell death and chronic inflammation promote tumor growth.
Discovery medicine 2004;4(24):448-56.
2004: Jukka Vakkila; Richard A DeMarco; Michael T Lotze
Imaging analysis of STAT1 and NF-kappaB translocation in dendritic cells at the single cell level.
Journal of immunological methods 2004;294(1-2):123-34.
2004: Jukka Vakkila; Michael T Lotze
Inflammation and necrosis promote tumour growth.
Nature reviews. Immunology 2004;4(8):641-8.
2004: Siamak Agha-Mohammadi; Mark O'Malley; Abrak Etemad; Zhong Wang; Xiao Xiao; Michael T Lotze
Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness.
The journal of gene medicine 2004;6(7):817-28.
2004: Muneo Numasaki; Michael T Lotze; Hidetada Sasaki
Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts.
Immunology letters 2004;93(1):39-43.
2004: Michael T Lotze; Robert C Rees
Identifying biomarkers and surrogates of tumors (cancer biometrics): correlation with immunotherapies and immune cells.
Cancer immunology, immunotherapy : CII 2004;53(3):256-61.
2003: Toru Kitagawa; Takashi Iwazawa; Paul D Robbins; Michael T Lotze; Hideaki Tahara
Advantages and limitations of particle-mediated transfection (gene gun) in cancer immuno-gene therapy using IL-10, IL-12 or B7-1 in murine tumor models.
The journal of gene medicine 2003;5(11):958-65.
2003: Masatoshi Eto; Jaafar Bennouna; Oriana C Hunter; Pamela A Hershberger; Tatsuya Kanto; Candace S Johnson; Michael T Lotze; Andrew A Amoscato
C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells.
The Prostate 2003;57(1):66-79.
2003: Young-Ik Son; Ramsey M Dallal; Michael T Lotze
Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(3):234-40.
2003: Muneo Numasaki; Jun-ichi Fukushi; Mayumi Ono; Satwant K Narula; Paul J Zavodny; Toshio Kudo; Paul D Robbins; Hideaki Tahara; Michael T Lotze
Interleukin-17 promotes angiogenesis and tumor growth.
Blood 2003;101(7):2620-7.
2003: Richard E Redlinger; Robbie B Mailliard; Michael T Lotze; Edward M Barksdale
Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Journal of pediatric surgery 2003;38(3):301-7; discussion 301-7.
2003: Wataru Hashimoto; Fumiaki Tanaka; Paul D Robbins; Masaru Taniguchi; Haruki Okamura; Michael T Lotze; Hideaki Tahara
Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL-18.
International journal of cancer. Journal international du cancer 2003;103(4):508-13.
2003: Wentao Gao; Sanjay Kumar; Michael T Lotze; Charles Hanning; Paul D Robbins; Andrea Gambotto
Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(1):107-13.
2002: Yuji Satoh; Clemens Esche; Andrea Gambotto; Galina V Shurin; Zoya R Yurkovetsky; Paul D Robbins; simon simon watkins; Satoru Todo; Ronald Herberman; Michael T Lotze; Michael R Shurin
Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.
Journal of experimental therapeutics & oncology 2002;2(6):337-49.
2002: Fumiaki Tanaka; Wataru Hashimoto; Paul D Robbins; Michael T Lotze; Hideaki Tahara
Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.
Gene therapy 2002;9(21):1480-6.
2002: Michael T Lotze; Thomas A Kost
Viruses as gene delivery vectors: application to gene function, target validation, and assay development.
Cancer gene therapy 2002;9(8):692-9.
2002: Hiromune Shimamura; Rachel Cumberland; Kazumasa Hiroishi; simon simon watkins; Michael T Lotze; Joseph Baar
Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):226-34.
2002: Michael T Lotze; Hideaki Tahara; Haruki Okamura
Interleukin-18 as a novel, distinct, and distant member of the interleukin-1 family promoting development of the adaptive immune response: the interleukin-18 issue of the Journal of Immunotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25 Suppl 1():S1-3.
2002: Robbie B Mailliard; Shinichi Egawa; Quan Cai; Anna Kalinska; Svetlana N Bykovskaya; Michael T Lotze; Martien L Kapsenberg; Walter J Storkus; Pawel Kalinski
Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses.
The Journal of experimental medicine 2002;195(4):473-83.
2002: Ramsey M Dallal; Peter Christakos; Kenneth Lee; Shinichi Egawa; Young-Ik Son; Michael T Lotze
Paucity of dendritic cells in pancreatic cancer.
Surgery 2002;131(2):135-8.
2002: Christine Odoux; Andreas Albers; Andrew A Amoscato; Michael T Lotze; Michael K K Wong
TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
International journal of cancer. Journal international du cancer 2002;97(4):458-65.
2001: C M Matsko; Oriana C Hunter; Hannah Rabinowich; Michael T Lotze; Andrew A Amoscato
Mitochondrial lipid alterations during Fas- and radiation-induced apoptosis.
Biochemical and biophysical research communications 2001;287(5):1112-20.
2001: S Fujii; K Shimizu; T Shimizu; Michael T Lotze
Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ.
Blood 2001;98(7):2143-51.
2001: Tatsuya Kanto; Pawel Kalinski; Oriana C Hunter; Michael T Lotze; Andrew A Amoscato
Ceramide mediates tumor-induced dendritic cell apoptosis.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(7):3773-84.
2001: Young-Ik Son; Robbie B Mailliard; simon simon watkins; Michael T Lotze
Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti-tumor effects when combined with interleukin-2.
The Laryngoscope 2001;111(8):1472-8.
2001: Hideho Okada; Lorissa Villa; Jason Attanucci; Melanie L Erff; Wendy Fellows; Michael T Lotze; Ian F Pollack; William Chambers
Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.
Gene therapy 2001;8(15):1157-66.
2001: T Shimizu; A Berhanu; Richard E Redlinger; S Watkins; Michael T Lotze; Edward M Barksdale
Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma.
Journal of pediatric surgery 2001;36(8):1285-92.
2001: Ramsey M Dallal; Michael T Lotze
Immunotherapy of metastasis.
Surgical oncology clinics of North America 2001;10(2):433-47, xi.
2001: Hideho Okada; Jason Attanucci; KM Giezeman-Smits; Cynthia S Brissette-Storkus; Wendy Fellows; Andrea Gambotto; L F Pollack; Kay L Pogue-Geile; Michael T Lotze; ME Bozik; William Chambers
Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
Cancer research 2001;61(6):2625-31.
2001: Robbie B Mailliard; Michael T Lotze
Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3 Suppl):980s-988s.
2001: Olivera J Finn; Michael T Lotze
A decade in the life of tumor immunology.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3 Suppl):759s-760s.
2001: Young-Ik Son; Ramsey M Dallal; Robbie B Mailliard; Shinichi Egawa; Z L Jonak; Michael T Lotze
Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells.
Cancer research 2001;61(3):884-8.
2001: Takashi Iwazawa; G Y Chau; T Mori; KA Dookeran; Joshua Rubin; S Watkins; Paul D Robbins; Michael T Lotze; Hideaki Tahara
Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: no additional benefit of using retroviral producer cell.
Cancer gene therapy 2001;8(1):17-22.
2001: Galina V Shurin; Michael R Shurin; Svetlana N Bykovskaia; Jeffrey Shogan; Michael T Lotze; E M Barksdale
Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.
Cancer research 2001;61(1):363-9.
2000: Ramsey M Dallal; Michael T Lotze
The dendritic cell and human cancer vaccines.
Current opinion in immunology 2000;12(5):583-8.
2000: Clemens Esche; Q Cai; J M Peron; Oriana C Hunter; Vladimir M Subbotin; Michael T Lotze; Michael R Shurin
Interleukin-12 and Flt3 ligand differentially promote dendropoiesis in vivo.
European journal of immunology 2000;30(9):2565-75.
2000: Fumiaki Tanaka; Wataru Hashimoto; Haruki Okamura; Paul D Robbins; Michael T Lotze; Hideaki Tahara
Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Cancer research 2000;60(17):4838-44.
2000: Georgi Pirtskhalaishvili; Galina V Shurin; Clemens Esche; Quan Cai; RR Salup; Svetlana N Bykovskaia; Michael T Lotze; Michael R Shurin
Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins.
British journal of cancer 2000;83(4):506-13.
2000: Robbie B Mailliard; Ramsey M Dallal; Young-Ik Son; Michael T Lotze
Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen.
Immunological investigations 2000;29(2):177-85.
2000: Elena Ranieri; Lisa S Kierstead; Hassane M Zarour; John M Kirkwood; Michael T Lotze; Theresa L Whiteside; Walter J Storkus
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading.
Immunological investigations 2000;29(2):121-5.
2000: KM Giezeman-Smits; Hideho Okada; Cynthia S Brissette-Storkus; L A Villa; Jason Attanucci; Michael T Lotze; Ian F Pollack; ME Bozik; William Chambers
Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Cancer research 2000;60(9):2449-57.
2000: Siamak Agha-Mohammadi; Michael T Lotze
Regulatable systems: applications in gene therapy and replicating viruses.
The Journal of clinical investigation 2000;105(9):1177-83.
2000: Siamak Agha-Mohammadi; Michael T Lotze
Immunomodulation of cancer: potential use of selectively replicating agents.
The Journal of clinical investigation 2000;105(9):1173-6.
2000: M Hirao; N Onai; Kazumasa Hiroishi; simon simon watkins; K Matsushima; Paul D Robbins; Michael T Lotze; Hideaki Tahara
CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes.
Cancer research 2000;60(8):2209-17.
2000: T Saito; Grzegorz Dworacki; William Gooding; Michael T Lotze; Theresa L Whiteside
Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1351-64.
2000: Hideho Okada; Jason Attanucci; Hideaki Tahara; Ian F Pollack; ME Bozik; William Chambers; Michael T Lotze
Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy.
Cancer gene therapy 2000;7(3):486-94.
2000: Hideho Okada; Ian F Pollack; Michael T Lotze; L Dade Lunsford; Douglas Kondziolka; Frank S Lieberman; David Schiff; Jason Attanucci; Howard D Edington; William Chambers; Paul Robbins; Joseph Baar; D Kinzler; Theresa L Whiteside; Elaine Elder
Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response.
Human gene therapy 2000;11(4):637-53.
2000: Michael T Lotze; Michael R Shurin; Clemens Esche; Hideaki Tahara; Walter J Storkus; John M Kirkwood; Theresa L Whiteside; Elaine Elder; H Okada; Paul D Robbins
Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity.
The cancer journal from Scientific American 2000;6 Suppl 1():S61-6.
2000: Kazumasa Hiroishi; Thomas Tüting; Michael T Lotze
IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(2):567-72.
1999: Kazumasa Hiroishi; Thomas Tüting; Hideaki Tahara; Michael T Lotze
Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Gene therapy 1999;6(12):1988-94.
1999: Clemens Esche; Vladimir M Subbotin; Oriana C Hunter; J M Peron; C Maliszewski; Michael T Lotze; Michael R Shurin
Differential regulation of epidermal and dermal dendritic cells by IL-12 and Flt3 ligand.
The Journal of investigative dermatology 1999;113(6):1028-32.
1999: Clemens Esche; Valeria P Makarenkova; Natalya Vsevolodovna Kost; Michael T Lotze; Andrey Aleksandrovich Zozulya; Michael R Shurin
Murine dendritic cells express functional delta-type opioid receptors.
Annals of the New York Academy of Sciences 1999;885():387-90.
1999: Joyce E Ohm; Michael R Shurin; Clemens Esche; Michael T Lotze; David P Carbone; Dmitry I Gabrilovich
Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(6):3260-8.
1999: Y Nishioka; M Hirao; Paul D Robbins; Michael T Lotze; Hideaki Tahara
Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.
Cancer research 1999;59(16):4035-41.
1999: Clemens Esche; Anna Lokshin; Galina V Shurin; BRIAN GASTMAN; Hannah Rabinowich; simon simon watkins; Michael T Lotze; Michael R Shurin
Tumor's other immune targets: dendritic cells.
Journal of leukocyte biology 1999;66(2):336-44.
1999: Michael T Lotze
Not just an antigen-presenting cell: 5th international symposium on dendritic cells in fundamental and clinical immunology.
Journal of leukocyte biology 1999;66(2):195-200.
1999: Wataru Hashimoto; T Osaki; Haruki Okamura; Paul D Robbins; M Kurimoto; S Nagata; Michael T Lotze; Hideaki Tahara
Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(2):583-9.
1999: Clemens Esche; Andrea Gambotto; Y Satoh; Valentin Gerein; Paul D Robbins; simon simon watkins; Michael T Lotze; Michael R Shurin
CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth.
European journal of immunology 1999;29(7):2148-55.
1999: Kazuaki Chikamatsu; Koji Nakano; Walter J Storkus; Ettore Appella; Michael T Lotze; Theresa L Whiteside; Albert B DeLeo
Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1281-8.
1999: T Osaki; Wataru Hashimoto; Andrea Gambotto; Haruki Okamura; Paul D Robbins; M Kurimoto; Michael T Lotze; Hideaki Tahara
Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18).
Gene therapy 1999;6(5):808-15.
1999: CC Wilson; Walter C Olson; T Tuting; Charles Rinaldo; Michael T Lotze; Walter J Storkus
HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(5):3070-8.
1999: Clemens Esche; Michael R Shurin; Michael T Lotze
The use of dendritic cells for cancer vaccination.
Current opinion in molecular therapeutics 1999;1(1):72-81.
1999: Hideho Okada; KM Giezeman-Smits; Hideaki Tahara; Jason Attanucci; Wendy Fellows; Michael T Lotze; William Chambers; ME Bozik
Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine.
Gene therapy 1999;6(2):219-26.
1999: Thomas Tüting; Andrea Gambotto; Albert B DeLeo; Michael T Lotze; Paul D Robbins; Walter J Storkus
Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice.
Cancer gene therapy 1999;6(1):73-80.
1999: Andrea Gambotto; Thomas Tüting; D L McVey; Imre Kovesdi; Hideaki Tahara; Michael T Lotze; Paul D Robbins
Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
Cancer gene therapy 1999;6(1):45-53.
1998: JM Péron; Clemens Esche; Vladimir M Subbotin; C Maliszewski; Michael T Lotze; Michael R Shurin
FLT3-ligand administration inhibits liver metastases: role of NK cells.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(11):6164-70.
1998: Andrew A Amoscato; D A Prenovitz; Michael T Lotze
Rapid extracellular degradation of synthetic class I peptides by human dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(8):4023-32.
1998: Hideho Okada; Hideaki Tahara; Michael R Shurin; Jason Attanucci; KM Giezeman-Smits; Wendy Fellows; Michael T Lotze; William Chambers; ME Bozik
Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.
International journal of cancer. Journal international du cancer 1998;78(2):196-201.
1998: Uma N M Rao; S H Hanan; Michael T Lotze; C P Karakousis
Distant skin and soft tissue metastases from sarcomas.
Journal of surgical oncology 1998;69(2):94-8.
1998: Kathleen Martincic; R Campbell; G Edwalds-Gilbert; Lina Souan; Michael T Lotze; Christine Milcarek
Increase in the 64-kDa subunit of the polyadenylation/cleavage stimulatory factor during the G0 to S phase transition.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(19):11095-100.
1998: S A Goldman; E Baker; R J Weyant; MR Clarke; Jeffrey N Myers; Michael T Lotze
Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma.
Archives of otolaryngology--head & neck surgery 1998;124(6):641-6.
1998: Bettina Couderc; L Zitvogel; Victorine Douin-Echinard; L Djennane; Hideaki Tahara; Gilles FAVRE; Michael T Lotze; Paul D Robbins
Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
Cancer gene therapy 1998;5(3):163-75.
1998: H N Vu; F W Jenkins; Steven H Swerdlow; Joseph Locker; Michael T Lotze
Pleural effusion as the presentation for primary effusion lymphoma.
Surgery 1998;123(5):589-91.
1998: Michael R Shurin; Clemens Esche; Michael T Lotze
FLT3: receptor and ligand. Biology and potential clinical application.
Cytokine & growth factor reviews 1998;9(1):37-48.
1998: Tjendimin Tjandrawan; D M Martin; Markus J Maeurer; Chiara Castelli; Michael T Lotze; Walter J Storkus
Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(2):149-57.
1998: Olivera J Finn; Michael T Lotze
Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer. Introduction.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(2):114-8.
1998: J S Goydos; AM Brumfield; E Frezza; A Booth; Michael T Lotze; Sally E Carty
Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker.
Annals of surgery 1998;227(3):398-404.
1998: T Osaki; JM Péron; Q Cai; Haruki Okamura; Paul D Robbins; M Kurimoto; Michael T Lotze; Hideaki Tahara
IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(4):1742-9.
1998: Thomas Tüting; CC Wilson; D M Martin; Yvette L Kasamon; Jennifer L Rowles; D I Ma; Craig L Slingluff; S N Wagner; P van der Bruggen; Joseph Baar; Michael T Lotze; Walter J Storkus
Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(3):1139-47.
1998: Jeffrey N Myers; A Mank-Seymour; L Zitvogel; W Storkus; M Clarke; C S Johnson; H Tahara; Michael T Lotze
Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice.
The Laryngoscope 1998;108(2):261-8.
1998: Clemens Esche; Vladimir M Subbotin; C Maliszewski; Michael T Lotze; Michael R Shurin
FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma.
Cancer research 1998;58(3):380-3.
1998: Galina V Shurin; Valentin Gerein; Michael T Lotze; E M Barksdale
Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand.
Natural immunity 1998;16(5-6):263-74.
1998: Victorine Douin-Echinard; Paul D Robbins; Michael T Lotze; Gilles FAVRE; Bettina Couderc
Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70.
Advances in experimental medicine and biology 1998;451():353-7.
1998: Thomas Tüting; CC Wilson; D M Martin; Joseph Baar; Albert B DeLeo; Michael T Lotze; Walter J Storkus
DNA vaccines targeting dendritic cells for the immunotherapy of cancer.
Advances in experimental medicine and biology 1998;451():295-304.
1997: Michael T Lotze; B Hellerstedt; L Stolinski; T Tueting; C Wilson; D Kinzler; H Vu; Joshua Rubin; Walter J Storkus; Hideaki Tahara; Elaine Elder; Theresa L Whiteside
The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy.
The cancer journal from Scientific American 1997;3 Suppl 1():S109-14.
1997: Thomas Tüting; Andrea Gambotto; Joseph Baar; I D Davis; Walter J Storkus; Paul J Zavodny; Satwant K Narula; Hideaki Tahara; Paul D Robbins; Michael T Lotze
Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models.
Gene therapy 1997;4(10):1053-60.
1997: Thomas Tüting; Albert B DeLeo; Michael T Lotze; Walter J Storkus
Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
European journal of immunology 1997;27(10):2702-7.
1997: Michael R Shurin; P P Pandharipande; tatiana Zorina; Catherine Haluszczak; Vladimir M Subbotin; Oriana C Hunter; AM Brumfield; Walter J Storkus; E Maraskovsky; Michael T Lotze
FLT3 ligand induces the generation of functionally active dendritic cells in mice.
Cellular immunology 1997;179(2):174-84.
1997: Thomas Tüting; Walter J Storkus; Michael T Lotze
Gene-based strategies for the immunotherapy of cancer.
Journal of molecular medicine (Berlin, Germany) 1997;75(7):478-91.
1997: KA Dookeran; Michael T Lotze; S S Sikora; Uma N M Rao
Pancreatic and ampullary carcinomas with intrascrotal metastases.
The British journal of surgery 1997;84(2):198-9.
1997: Markus J Maeurer; Wolfgang Walter; D Martin; L Zitvogel; Elaine Elder; Walter J Storkus; Michael T Lotze
Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes.
Scandinavian journal of immunology 1997;45(2):182-92.
1997: Michael R Shurin; Clemens Esche; JM Péron; Michael T Lotze
Antitumor activities of IL-12 and mechanisms of action.
Chemical immunology 1997;68():153-74.
1997: Michael T Lotze; Michael R Shurin; I Davis; Andrew A Amoscato; Walter J Storkus
Dendritic cell based therapy of cancer.
Advances in experimental medicine and biology 1997;417():551-69.
1997: Thomas Tüting; tatiana Zorina; D I Ma; CC Wilson; C M De Cesare; Albert B De Leo; Michael T Lotze; Walter J Storkus
Development of dendritic cell-based genetic vaccines for cancer.
Advances in experimental medicine and biology 1997;417():511-8.
1997: José I Mayordomo; tatiana Zorina; Walter J Storkus; L Zitvogel; Maria Dolores Garcia-Prats; Albert B DeLeo; Michael T Lotze
Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines.
Stem cells (Dayton, Ohio) 1997;15(2):94-103.
1996: Markus J Maeurer; H W Chan; Julia Karbach; Russell D Salter; Alexander Knuth; Michael T Lotze; Walter J Storkus
Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
European journal of immunology 1996;26(11):2613-23.
1996: Michael T Lotze; L Zitvogel; R Campbell; Paul D Robbins; Elaine Elder; Catherine Haluszczak; D Martin; Theresa L Whiteside; Walter J Storkus; Hideaki Tahara
Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials.
Annals of the New York Academy of Sciences 1996;795():440-54.
1996: L Zitvogel; Bettina Couderc; José I Mayordomo; Paul D Robbins; Michael T Lotze; Walter J Storkus
IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo.
Annals of the New York Academy of Sciences 1996;795():284-93.
1996: Hideaki Tahara; L Zitvogel; Walter J Storkus; Paul D Robbins; Michael T Lotze
Murine models of cancer cytokine gene therapy using interleukin-12.
Annals of the New York Academy of Sciences 1996;795():275-83.
1996: Michael T Lotze
Interleukin 12: cellular and molecular immunology of an important regulatory cytokine. Introduction.
Annals of the New York Academy of Sciences 1996;795():xiii-xix.
1996: Markus J Maeurer; Susanne M Gollin; D Martin; William P Swaney; J Bryant; Chiara Castelli; Paul Robbins; G Parmiani; Walter J Storkus; Michael T Lotze
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.
The Journal of clinical investigation 1996;98(7):1633-41.
1996: H Bernhard; Markus J Maeurer; Elke Jäger; Thomas Wölfel; J Schneider; Julia Karbach; Barbara Seliger; Christoph Huber; W S Storkus; Michael T Lotze; K H Meyer zum Büschenfelde; Alexander Knuth
Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma.
Scandinavian journal of immunology 1996;44(3):285-92.
1996: R M Berman; T Suzuki; Hideaki Tahara; Paul D Robbins; S K Narula; Michael T Lotze
Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(1):231-8.
1996: Christopher H Evans; Paul D Robbins; Steven C Ghivizzani; James H Herndon; Richard Kang; Alfred B Bahnson; John A Barranger; E M Elders; S Gay; Matthew M Tomaino; Mary Chester Wasko; simon simon watkins; Theresa L Whiteside; Joseph C Glorioso; Michael T Lotze; T M Wright
Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis.
Human gene therapy 1996;7(10):1261-80.
1996: J S Goydos; Elaine Elder; Theresa L Whiteside; Olivera J Finn; Michael T Lotze
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma.
The Journal of surgical research 1996;63(1):298-304.
1996: L Zitvogel; Paul D Robbins; Walter J Storkus; MR Clarke; Markus J Maeurer; R L Campbell; C G Davis; Hideaki Tahara; R D Schreiber; Michael T Lotze
Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.
European journal of immunology 1996;26(6):1335-41.
1996: Markus J Maeurer; Susanne M Gollin; Walter J Storkus; William P Swaney; Julia Karbach; D Martin; Chiara Castelli; R Salter; Alexander Knuth; Michael T Lotze
Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(4):641-52.
1996: Markus J Maeurer; D Martin; Wolfgang Walter; K Liu; L Zitvogel; K Halusczcak; Hannah Rabinowich; R Duquesnoy; Walter J Storkus; Michael T Lotze
Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.
The Journal of experimental medicine 1996;183(4):1681-96.
1996: José I Mayordomo; D J Loftus; H Sakamoto; C M De Cesare; PM Appasamy; Michael T Lotze; Walter J Storkus; Ettore Appella; Albert B DeLeo
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
The Journal of experimental medicine 1996;183(4):1357-65.
1996: Michael T Lotze
Cytokine gene therapy of cancer.
The cancer journal from Scientific American 1996;2(2):63-72.
1996: Elaine Elder; Michael T Lotze; Theresa L Whiteside
Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer.
Human gene therapy 1996;7(4):479-87.
1996: Markus J Maeurer; Walter J Storkus; John M Kirkwood; Michael T Lotze
New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines.
Melanoma research 1996;6(1):11-24.
1996: Jeffrey N Myers; S Yasumura; Yoshinori Suminami; H Hirabayashi; W c Lin; Jonas T Johnson; Michael T Lotze; Theresa L Whiteside
Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):127-35.
1996: Markus J Maeurer; D Martin; Elaine Elder; Walter J Storkus; Michael T Lotze
Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):87-95.
1996: G H Leder; M Oppenheim; M Rosenstein; N Shah; R Hoffman; Michael T Lotze; H G Beger
Inhibition of nitric oxide synthesis does not improve interleukin-2-mediated antitumor effects in vivo.
European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes 1996;28(3):167-78.
1996: L Zitvogel; José I Mayordomo; T Tjandrawan; Albert B DeLeo; MR Clarke; Michael T Lotze; Walter J Storkus
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
The Journal of experimental medicine 1996;183(1):87-97.
1996: Christina Celluzzi; José I Mayordomo; Walter J Storkus; Michael T Lotze; Louis Falo
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
The Journal of experimental medicine 1996;183(1):283-7.
1995: Hideaki Tahara; Michael T Lotze; Paul D Robbins; Walter J Storkus; L Zitvogel
IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts.
Human gene therapy 1995;6(12):1607-24.
1995: L Zitvogel; Michael T Lotze
Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application.
Research in immunology 1995;146(7-8):628-38.
1995: G H Leder; M Oppenheim; M Rosenstein; Michael T Lotze; H G Beger
Addition of interleukin 12 to low dose interleukin 2 treatment improves antitumor efficacy in vivo.
Zeitschrift für Gastroenterologie 1995;33(9):499-502.
1995: Markus J Maeurer; D M Martin; Chiara Castelli; Elaine Elder; G Leder; Walter J Storkus; Michael T Lotze
Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.
Cancer immunology, immunotherapy : CII 1995;41(2):111-21.
1995: L Zitvogel; Hideaki Tahara; Paul D Robbins; Walter J Storkus; MR Clarke; M A Nalesnik; Michael T Lotze
Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
Journal of immunology (Baltimore, Md. : 1950) 1995;155(3):1393-403.
1995: T Suzuki; Hideaki Tahara; S Narula; K W Moore; Paul D Robbins; Michael T Lotze
Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors.
The Journal of experimental medicine 1995;182(2):477-86.
1995: Markus J Maeurer; S Hurd; D M Martin; Walter J Storkus; Michael T Lotze
Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage.
The cancer journal from Scientific American 1995;1(2):162-70.
1995: Joshua Rubin; Michael T Lotze; D Rosenfelder; A Brumfield; R Howells; R Schwartz; S Sylvestri; J Sammon; K Bron; P Orens
Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial.
Annals of surgical oncology 1995;2(4):351-9.
1995: Hideaki Tahara; L Zitvogel; Walter J Storkus; H J Zeh; T G McKinney; R D Schreiber; U Gubler; Paul D Robbins; Michael T Lotze
Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(12):6466-74.
1995: Q Cai; Joshua Rubin; Michael T Lotze
Genetically marking human cells--results of the first clinical gene transfer studies.
Cancer gene therapy 1995;2(2):125-36.
1995: Markus J Maeurer; L Zitvogel; Elaine Elder; Walter J Storkus; Michael T Lotze
Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA.
Natural immunity 1995;14(4):188-97.
1995: Hideaki Tahara; Michael T Lotze
Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Gene therapy 1995;2(2):96-106.
1995: I Pappo; H Tahara; P D Robbins; M K Gately; Stanley Wolf; A Barnea; Michael T Lotze
Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy.
The Journal of surgical research 1995;58(2):218-26.
1995: Joshua Rubin; R Day; Rene J Duquesnoy; B Simonis; S Adams; J Lee; Michael T Lotze
HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2.
Therapeutic immunology 1995;2(1):1-6.
1995: Chiara Castelli; Walter J Storkus; Markus J Maeurer; D M Martin; E C Huang; B N Pramanik; TL Nagabhushan; Giorgio Parmiani; Michael T Lotze
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.
The Journal of experimental medicine 1995;181(1):363-8.
1995: M A Frassanito; José I Mayordomo; R M DeLeo; Walter J Storkus; Michael T Lotze; Albert B DeLeo
Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
Cancer research 1995;55(1):124-8.
1994: L Zitvogel; Hideaki Tahara; Q Cai; Walter J Storkus; G Muller; Stanley Wolf; M Gately; Paul D Robbins; Michael T Lotze
Construction and characterization of retroviral vectors expressing biologically active human interleukin-12.
Human gene therapy 1994;5(12):1493-506.
1994: T Itoh; Walter J Storkus; Elieser Gorelik; Michael T Lotze
Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(3):1202-15.
1994: P S Strumph; Sally E Carty; H L Rilo; P B Carroll; Camillo Ricordi; Michael T Lotze
Interleukin-1 receptor antagonist is not detrimental to human islet cell insulin secretion but decreases insulin content.
Transplantation proceedings 1994;26(2):694.
1994: M H Oppenheim; Michael T Lotze
Interleukin-2: solid-tumor therapy.
Oncology 1994;51(2):154-69.
1994: G Stuber; G H Leder; W T Storkus; Michael T Lotze; Susanne Modrow; L Székely; Hans Wolf; Eva Klein; Klas Kärre; George Klein
Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
European journal of immunology 1994;24(3):765-8.
1994: B A Pippin; M Rosenstein; W F Jacob; Y Chiang; Michael T Lotze
Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
Cancer gene therapy 1994;1(1):35-42.
1994: H J Zeh; G H Leder; Michael T Lotze; Russell D Salter; M Tector; G Stuber; Susanne Modrow; Walter J Storkus
Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2.
Human immunology 1994;39(2):79-86.
1994: Michael T Lotze; Joshua Rubin; S Carty; H Edington; P Ferson; R Landreneau; B Pippin; M Posner; D Rosenfelder; C Watson
Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response.
Human gene therapy 1994;5(1):41-55.
1994: Hideaki Tahara; H J Zeh; Walter J Storkus; I Pappo; simon simon watkins; U Gubler; Stanley Wolf; Paul D Robbins; Michael T Lotze
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
Cancer research 1994;54(1):182-9.
1993: Jay Hunt; B A Pippin; Rodney J Landreneau; W F Jacob; Michael T Lotze; Jill M Siegfried
Transfer and expression of the human interleukin-4 gene in carcinoma and stromal cell lines derived from lung cancer patients.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(4):314-21.
1993: Walter J Storkus; H J Zeh; Markus J Maeurer; Russell D Salter; Michael T Lotze
Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(7):3719-27.
1993: H J Zeh; S Hurd; Walter J Storkus; Michael T Lotze
Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(2):155-61.
1993: Walter J Storkus; H J Zeh; Russell D Salter; Michael T Lotze
Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(2):94-103.
1993: E Weidmann; Elaine Elder; Massimo Trucco; Michael T Lotze; Theresa L Whiteside
Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma.
International journal of cancer. Journal international du cancer 1993;54(3):383-90.
1992: H Tahara; G M Mueller; Camillo Ricordi; Paul D Robbins; Michael T Lotze
Islet cell transplantation facilitated by gene transfer.
Transplantation proceedings 1992;24(6):2975-6.
1992: Michael T Lotze; Joshua Rubin; H J Zeh
New biologic agents come to bat for cancer therapy.
Current opinion in oncology 1992;4(6):1116-23.
1992: Michael T Lotze; H J Zeh; Elaine Elder; Q Cai; B A Pippin; M M Rosenstein; Theresa L Whiteside; Ronald Herberman
Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(3):212-7.
1992: Michael T Lotze
Keystone symposium. Melanoma and biology of the neural crest. Taos City Hall, Taos, New Mexico, USA, 1-8 February 1992.
Melanoma research 1992;2(2):131-8.
1992: Joshua Rubin; Michael T Lotze
Immune function and dysfunction. A primer for the radiologist.
Radiologic clinics of North America 1992;30(3):507-23.
1992: Michael T Lotze
T-cell growth factors and the treatment of patients with cancer.
Clinical immunology and immunopathology 1992;62(1 Pt 2):S47-54.